Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging

Journal of Neuroscience Research

Volumn 86, Issue 12, 2008, Pages 2784-2791

  Scholtzowa, Henrieta ^a   Wadghiri, Youssef Z ^a   Douadi, Moustafa ^a   Sigurdsson, Einar M ^a   Li, Yong Sheng ^a   Quartermain, David ^a   Banerjee, Pradeep ^b   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Micromagnetic resonance imaging; NMDA antagonist

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; GADOLINIUM PENTETATE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRESENILIN 1;

ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; COGNITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EX VIVO STUDY; HISTOPATHOLOGY; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TRANSGENIC MOUSE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; MAGNETIC RESONANCE IMAGING; MEMANTINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECOGNITION (PSYCHOLOGY);

EID: 57049085109     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21713     Document Type: Article

References (32)

1. Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM. 2006. Aβ derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur J Neurosci 24:2530-2542.
2. Banerjee PK, Lahiri DK, Tanila H, Miguel-Hidalgo JJ, Iqbal K. 2005. Preclinical basis for the efficacy of memantine in Alzheimer's disease. Biol Psychiatry 57:173S-174S.
3. Barnes CA, Danysz W, Parsons CG. 1996. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8:565-571.
4. Blennow K, De Leon MJ, Zetterberg H. 2006. Alzheimer's disease. Lancet 368:387-403.
5. Chohan MO, Iqbal K. 2006. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer's disease. J Alzheimers Dis 10:81-87.
6. Danysz W, Parsons CG. 2003. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 18:S23-S32.
7. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. 2007. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601.
8. Degerman GM, Kilander L, Basun H, Lannfelt L. 2007. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 24:247-252.
9. Frick KM, Gresack JE. 2003. Sex differences in the behavioral response to spatial and object novelty in adult C57BL/6 mice. Behav Neurosci 117:1283-1291.
10. Hynd MR, Scott HL, Dodd PR. 2004. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45:583-595.
11. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. 2007. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796-807.
12. Lahiri DK, Alley GM, Chen DM, Ge YW, Farlow MR, Banerjee PK. 2003a. Effects of memantine on the beta-amyloid precursor protein. Biol Psychiatry 53:112S.
13. Lahiri DK, Alley GM, Morgan C, Banerjee PK, Farlow MR. 2003b. Effect of memantine on levels of the amyloid beta peptide in cell cultures. J Neurochem 85:42.
14. Lahiri DK, Chen D, Alley GM, Banerjee PK. 2006. Effects of memantine on the activity of secretase enzymes in human neuroblastoma cells. Eur Neuropsychopharmacol 16:S483-S484.
15. Lesne S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG, Plotkine M, Marchand-Verrecchia C, Vivien D, Buisson A. 2005. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci 25:9367-9377.
16. Lipton SA. 2007. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 8:621-632.
17. Lipton SA, Gu Z, Nakamura T. 2007. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 82:1-27.
18. Magnitsky S, Watson DJ, Walton RM, Pickup S, Bulte JW, Wolfe JH, Poptani H. 2005. In vivo and ex vivo MRI detection of localized and disseminated neural stem cell grafts in the mouse brain. Neuroimage 26:744-754.
19. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. 2002. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 958:210-221.
20. Minkeviciene R, Banerjee P, Tanila H. 2004. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 311:677-682.
21. Parsons CG, Danysz W, Quack G. 1999. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38:735-767.
22. Radde R, Bolmont T, Kaeser S, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haas C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M. 2006. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7:940-946.
23. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. 2003. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341.
24. Robinson DM, Keating GM. 2006. Memantine: a review of its use in Alzheimer's disease. Drugs 66:1515-1534.
25. Sadowski M, Wisniewski T. 2007. Disease modifying approaches for Alzheimer's pathology. Curr Pharmaceutic Design 13:1943-1954.
26. Sadowski M, Pankiewicz J, Scholtzova H, Mehta P, Prelli F, Quarter-main D, Wisniewski T. 2006. Blocking the apolipoproteinE/amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci U S A 103:18787-18792.
27. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875.
28. Sigurdsson E, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, Tsui WH, Sadowski M, Turnbull D, de Leon M, Wisniewski T. 2008. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging. 29:836-847.
29. Unger C, Svedberg MM, Yu WF, Hedberg MM, Nordberg A. 2006. Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice. J Pharmacol Exp Ther 317:30-36.
30. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliot JI, Li Q, Scholtzova H, Tang CY, Aguinaldo JG, Pappolla M, Duff K, Turnbull D, Wisniewski T. 2003. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 50:293-302.
31. Wadghiri YZ, Sigurdsson EM, Wisniewski T, Turnbull D. 2005. MR imaging of amyloid plaques in transgenic mice. In: Sigurdsson EM, editor. Amyloid proteins: methods and protocols. Totowa, NJ: Humana Press Inc. p 365-379.
32. Wisniewski T, Sigurdsson EM. 2007. Therapeutic approaches for prion and Alzheimer's diseases. FEBS J 274:3784-3798.